Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 May;89(5):438-444.
doi: 10.1007/s12098-021-03826-1. Epub 2021 Aug 16.

Liver Transplantation: A Safe and Definitive Alternative to Lifelong Nitisinone for Tyrosinemia Type 1

Jagadeesh Menon  1 , Naresh Shanmugam  2 , Joseph J Valamparampil  1 , Abdul Hakeem  3 , Mukul Vij  4 , Anil Jalan  5 , Mettu Srinivas Reddy  3 , Mohamed Rela  3   6
Affiliations

Liver Transplantation: A Safe and Definitive Alternative to Lifelong Nitisinone for Tyrosinemia Type 1

Jagadeesh Menon et al. Indian J Pediatr. 2022 May.

Abstract

Objectives: To report the experience of liver transplantation (LT) for tyrosinemia type 1 (TT-1).

Methods: Clinical data of children with TT-1 who underwent living donor LT between July 2009 and May 2020 were retrospectively analyzed. Data included pre-LT nitisinone therapy, graft type, post-LT complications, HCC incidence, and graft/patient survival.

Results: Nine children were diagnosed with TT-1 at a median age of 12 mo (6-54 mo). Nitisinone was started in 6 patients at a median age of 15 mo (6-42 mo), but all had frequent interruption of therapy due to logistics with drug procurement including its cost. Median age at transplantation was 5 y (2-11 y). Explant liver showed HCC in 5 patients (55% of total cohort). The graft and patient survival are 100% with median follow-up of 58 mo (24-84 mo).

Conclusion: LT is curative for TT-1 and excellent results can be obtained in experienced centers. This is especially favorable in countries with limited resources where the cost of medical therapy is highly prohibitive, with lifelong diet restrictions and unclear long-term risk of HCC.

Keywords: Hepatocellular carcinoma; Immunosuppression; Liver transplantation; Nitisinone; Patient survival; Tyrosinemia type 1.

PubMed Disclaimer

Comment in

References

    1. Chinsky JM, Singh R, Ficicioglu C, et al. Diagnosis and treatment of tyrosinemia type I: a US and Canadian consensus group review and recommendations. Genet Med. 2017;19. https://doi.org/10.1038/gim.2017.101 .
    1. Arnon R, Kerkar N, Davis MK, et al. Liver transplantation in children with metabolic diseases: the studies of pediatric liver transplantation experience: liver transplantation in childhood metabolic disease. Pediatr Transplant. 2010;14:796–805. - DOI
    1. Arnon R, Annunziato R, Miloh T, et al. Liver transplantation for hereditary tyrosinemia type I: analysis of the UNOS database: liver transplantation for tyrosinemia. Pediatr Transplant. 2011;15:400–5. - DOI
    1. Couce ML, Dalmau J, del Toro M, et al. Spanish working group on tyrosinemia type 1yrosinemia type 1 in Spain: mutational analysis, treatment and long-term outcome. Pediatr Int. 2011;53:985–9. - DOI
    1. Larochelle J, Alvarez F, Bussières JF, et al. Effect of nitisinone (NTBC) treatment on the clinical course of hepatorenal tyrosinemia in Québec. Mol Genet Metab. 2012;107:49–54. - DOI

LinkOut - more resources